Timothy L. Cannon, MD
Several pivotal studies have recently read out in the gastric/ gastroesophageal junction (GEJ) cancers space—all of them bearing clinical implications for oncologists, said Timothy L. Cannon, MD, and future research will likely focus on bringing novel combinations forward in the paradigm.
State of the Science Summit™ on Gastrointestinal Cancers, Cannon, a medical oncologist at Inova Medical Group, discussed how these pivotal clinical trials have impacted the gastric cancer treatment landscape.
OncLive®: What are some recent clinical trials in this space worth highlighting?
: I focused on a few larger trials that I thought had the most significant clinical implications for oncologists in 2019. The first one is the TAGS trial, which is a phase III study comparing the use of TAS-102 with placebo in the third-line treatment of [patients with] gastric cancer. That trial showed an OS benefit of approximately 2 months. The therapy was generally well tolerated other than some bone marrow suppression. As such, [TAS-102] may be a reasonable treatment option in the third-line setting for these patients.
... to read the full story